Journal
FRONTIERS IN PHARMACOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2018.01519
Keywords
cardiomyocyte hypertrophy; SIRT6; deacetylase activity; NFATc4; BNP
Categories
Funding
- National Natural Science Foundation of China [81473205, 81673433]
- National Engineering and Technology Research Center for New Drug Druggability Evaluation (Seed Program of Guangdong Province)
- Major Project of Guangdong Provincial Department of Science and Technology [2015B020232009, 2014B020210003, 2013B090700010]
- Major Project of Platform Construction Education Department of Guangdong Province [2014GKPT002]
- Guangzhou Science and Technology Program Project [201604020121]
- Guangdong Provincial Key Laboratory of Construction Foundation [2017B030314030]
Ask authors/readers for more resources
NFATc4, a member from the Nuclear Factor of Activated T cells (NFATs) transcription factor family, plays a pivotal role in the development of cardiac hypertrophy. NFATc4 is dephosphorylated by calcineurin and translocated from the cytoplasm to the nucleus to regulate the expression of hypertrophic genes, like brain natriuretic polypeptide (BNP). The present study identified SIRT6, an important subtype of NAD(+) dependent class III histone deacetylase, to be a negative regulator of NFATc4 in cardiomyocyte hypertrophy. In phenylephrine (PE)-induced hypertrophic cardiomyocyte model, over-expression of SIRT6 by adenovirus infection or by plasmid transfection repressed the protein and mRNA expressions of NFATc4, elevated its phosphorylation level, prevented its nuclear accumulation, subsequently suppressed its transcriptional activity and down-regulated its target gene BNP. By contrast, mutant of SIRT6 without deacetylase activity (H133Y) did not demonstrate these effects, suggesting that the inhibitory effect of SIRT6 on NFATc4 was dependent on its deacetylase activity. Moreover, the effect of SIRT6 over-expression on repressing BNP expression was reversed by NFATc4 replenishment, whereas the effect of SIRT6 deficiency on up-regulating BNP was recovered by NFATc4 silencing. Mechanistically, interactions between SIRT6 and NFATc4 might possibly facilitate the deacetylation of NFATc4 by SIRT6, thereby preventing the activation of NFATc4. In conclusion, the present study reveals that SIRT6 suppresses the expression and activation of NFATc4. These findings provide more evidences of the anti-hypertrophic effect of SIRT6 and suggest SIRT6 as a potential therapeutic target for cardiac hypertrophy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available